Ainos (AIMD) Competitors $0.45 +0.01 (+2.50%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends AIMD vs. SNTI, LSB, CMMB, INKT, CLDI, EQ, MTEX, ATHA, PULM, and LSTAShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Senti Biosciences (SNTI), Lakeshore Biopharma (LSB), Chemomab Therapeutics (CMMB), MiNK Therapeutics (INKT), Calidi Biotherapeutics (CLDI), Equillium (EQ), Mannatech (MTEX), Athira Pharma (ATHA), Pulmatrix (PULM), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Senti Biosciences Lakeshore Biopharma Chemomab Therapeutics MiNK Therapeutics Calidi Biotherapeutics Equillium Mannatech Athira Pharma Pulmatrix Lisata Therapeutics Ainos (NASDAQ:AIMD) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment. Which has more risk & volatility, AIMD or SNTI? Ainos has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. Do insiders and institutionals hold more shares of AIMD or SNTI? 25.7% of Senti Biosciences shares are held by institutional investors. 10.4% of Ainos shares are held by insiders. Comparatively, 15.9% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings & valuation, AIMD or SNTI? Ainos has higher earnings, but lower revenue than Senti Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$40.63K153.64-$13.77MN/AN/ASenti Biosciences$2.56M7.12-$71.06M-$15.56-0.26 Does the media refer more to AIMD or SNTI? In the previous week, Senti Biosciences had 3 more articles in the media than Ainos. MarketBeat recorded 3 mentions for Senti Biosciences and 0 mentions for Ainos. Ainos' average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score. Company Overall Sentiment Ainos Neutral Senti Biosciences Neutral Do analysts recommend AIMD or SNTI? Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 151.89%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor AIMD or SNTI? Senti Biosciences received 4 more outperform votes than Ainos when rated by MarketBeat users. CompanyUnderperformOutperformAinosN/AN/ASenti BiosciencesOutperform Votes440.00% Underperform Votes660.00% Is AIMD or SNTI more profitable? Senti Biosciences has a net margin of 0.00% compared to Ainos' net margin of -15,348.14%. Ainos' return on equity of -75.16% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ainos-15,348.14% -75.16% -50.22% Senti Biosciences N/A -154.84%-77.42% SummarySenti Biosciences beats Ainos on 10 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.09M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / Sales153.64196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book0.095.094.784.78Net Income-$13.77M$151.83M$120.31M$225.60M7 Day Performance2.52%-2.14%-1.92%-1.23%1 Month Performance-3.18%-4.56%13.65%0.46%1 Year Performance-76.87%8.87%28.34%15.24% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinosN/A$0.45+2.5%N/A-80.1%$6.09M$40,633.000.0046Gap UpSNTISenti Biosciences2.3348 of 5 stars$5.11-8.3%$10.00+95.7%-9.6%$23.45M$2.56M-0.334News CoverageGap DownLSBLakeshore Biopharma0.5039 of 5 stars$2.50flatN/AN/A$23.28M$80.82M0.00773News CoverageGap UpCMMBChemomab Therapeutics3.3225 of 5 stars$1.61+1.9%$7.33+355.5%+242.9%$23.12MN/A-1.6120Positive NewsINKTMiNK Therapeutics2.2354 of 5 stars$0.58-6.5%$6.50+1,020.7%-48.4%$22.94MN/A-1.4930Gap UpCLDICalidi Biotherapeutics2.3407 of 5 stars$1.75-5.4%$16.67+852.4%N/A$22.89M$50,000.000.0041News CoverageGap DownEQEquillium2.7452 of 5 stars$0.64-8.6%$5.00+681.3%-7.7%$22.68M$45.91M-4.5740Gap DownMTEXMannatech0.2131 of 5 stars$12.02+15.2%N/A+56.8%$22.60M$131.96M-14.84250Analyst ForecastGap UpATHAAthira Pharma2.1057 of 5 stars$0.58-1.3%$13.83+2,295.8%-71.9%$22.33MN/A-0.2040PULMPulmatrix0.1939 of 5 stars$6.04+5.0%N/A+198.5%$22.06M$10.01M-2.2920Analyst ForecastNews CoverageLSTALisata Therapeutics1.8982 of 5 stars$2.61+1.2%$15.00+474.9%-4.9%$21.90MN/A-1.0430 Related Companies and Tools Related Companies SNTI Competitors LSB Competitors CMMB Competitors INKT Competitors CLDI Competitors EQ Competitors MTEX Competitors ATHA Competitors PULM Competitors LSTA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AIMD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
